An easy method for developing fusion enabled SARS-CoV2 virus fusion mimic (SCFM), bypassing the need of Bio Safety Level (BSL) facility

An easy method for developing fusion enabled SARS-CoV2 virus fusion mimic (SCFM), bypassing the need of Bio Safety Level (BSL) facility

Widespread infection due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has led to a global pandemic. Currently, various approaches are being taken up to develop vaccines and therapeutics to treat SARS-CoV2 infection. Consequently, the S protein has become an important target protein...

Full description

Bibliographic Details
Main Authors: Abhishek Das, Satarupa Dutta, Dewanshu Sharma, Amit Pal, Nirmalya Ganguli, Subeer S. Majumdar
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Bioengineered
Subjects:
covid19
sars-cov2
s protein
syncytia
fusion
fusion mimic
Online Access:http://dx.doi.org/10.1080/21655979.2021.1955509

Similar Items

Similar Items